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Background: The purpose of this study was to investigate the in vitro and in vivo characteristics 
of a new tumor-targeted nanosized delivery carrier for antisense oligonucleotide (ASON).
Methods: Polyethylenimine (PEI) was used to condense ASON to form nanosized complexes 
(PEI/ASON), which were then modified using asparagine-glycine-arginine (NGR) peptide to 
obtain a tumor-targeted nanosized delivery carrier (NGR/PEI/ASON). The conditions required 
to form PEI/ASON were investigated.
Results: A linear correlation between the natural logarithm of the N/P ratio (PEI to ASON) 
and the zeta potential of the PEI/ASON complexes was found, ranging from 1.5 to 5.0. The pH 
of the solution strongly influenced the zeta potential of the PEI/ASON complexes. PEI/ASON 
and NGR/PEI/ASON were stable in RPMI-1640 culture medium in the presence of Dextran 70. 
Incorporation of ASON into PEI/ASON and NGR/PEI/ASON complexes prevented degradation 
of ASON by DNase I.
Conclusion: Both ASON/PEI and NGR/PEI/ASON complexes enhanced the uptake of ASON 
by EC9706 cells in vitro. In vivo, NGR/PEI/ASON complexes had the ability to target tumor 
tissues effectively.
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Introduction
Treating tumors using targeting genes could halt tumor progression without toxicity 
to normal cells. Therefore, gene therapy is considered a promising therapeutic strategy 
for malignant tumors and genetic diseases, and has been studied worldwide for the 
past two decades.1 Antisense oligonucleotide (ASON) to inhibit mRNA expression 
has been studied as a potentially important gene therapy in recent years.2,3
ASONs4,5 have shown promising results as agents for specific manipulation of 
genes to inhibit gene expression in vitro and in vivo. However, the development of 
antisense therapeutics has been frustrated by poor bioavailability as a result of degra-
dation of DNA by nucleases and insufficient affinity for target cells.6
Although viral gene carriers are highly effective, their fundamental shortcomings, 
such as toxicity, limited capacity to carry DNA, potential for virus recombination, and 
high cost, limit their practical application in gene therapy. Therefore, researchers have 
recently paid more attention to nonviral carriers with the characteristics of safety, low 
cost, easy modification, and lack of immunogenicity and mutagenesis.7,8 However, 
traditional nonviral gene carriers, such as bare DNA, liposome or cationic polymers, 
and cationic lipids, have low transfer efficacy.9International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Polyethylenimine (PEI) is one of the most efficient 
  nontargeted polycations used for gene delivery. PEI and its 
derivatives are generally known to be effective dispersants 
and cationic flocculants, and are believed to interact with 
negatively charged colloids. PEI, with its high positive charge 
density in aqueous solution, has recently been considered as 
a promising candidate for delivery of negatively charged 
DNA molecules. The relatively high efficacy of PEI is 
believed to stem from its high amine density and buffering 
capacity. PEI forms complexes with DNA as a result of 
electrostatic interactions between the ammonium groups of 
PEI and the phosphate groups of DNA.10
Traditional approaches to cancer therapy have focused 
on targeting and destroying cancer cells.11 However, direct 
access to cancer cells is often restricted, leading to limited 
success of various agents, including DNA and RNA. To over-
come this barrier, recent strategies have attempted to target 
the tumor vasculature instead of the cancer cells. Suppression 
of new blood vessel formation (anti-angiogenic therapy) and 
destruction of established tumor vasculature (antivascular 
therapy) have both been explored. Lack of a functional vas-
culature leads to tumor starvation and eventually to tumor 
regression. Thus, drug therapy targeted to the tumor vascu-
lature has emerged as one of the most promising approaches 
for the treatment of cancer.
Endothelial cells in the angiogenic vessels within solid 
tumors express several proteins that are absent or barely 
detectable in other blood vessels,12 including integrin αvβ3 
and αvβ5, aminopeptidase, vascular endothelial growth factor 
receptor, matrix metalloproteinase, proteoglycan, and 
prostate-specific membrane antigen. Some of these are 
already used as targets for tumor-specific delivery of thera-
peutic agents. Among the various new targeting ligands 
identified, peptides containing the asparagine-glycine- 
arginine (NGR) motif have been shown to home into tumors 
by binding to CD13. Although there are several subpopula-
tions of CD13, which are relatively widely distributed in the 
body, only one isoform is believed to be the receptor for 
NGR peptide. This isoform has been shown to be expressed 
exclusively in the neovasculature of tumor tissue. Ever since 
the discovery of NGR tumor-homing peptide ligand, 
researchers have used this ligand as a target for the delivery 
of various antitumor compounds, including chemotherapeutic 
drugs, apoptotic peptides, viral particles, and cytokines. NGR 
peptide targets tumor vessels by binding to the CD13-specific 
isoform.13,14
A new strategy for the condensation of ASON was devel-
oped in this study to generate a tumor-targeted delivery 
system for ASON. PEI were used to condense ASON into 
nanoscale PEI/ASON complexes modified with NGR peptide 
(NGR/PEI/ASON). The preparation conditions, including 
N/P ratio, buffer solution, ASON concentration, and pH, 
were optimized in the study. The characteristics of PEI/
ASON and NGR/PEI/ASON complexes were investigated 
in an esophageal carcinoma cell line and an established 
esophageal carcinoma model in nude mice.
Methods and materials
Materials
hTERT ASON, 5′-CCGCCCTCTCCTCGCGGCGCGAGTT-3′ 
complementary to the hTERT gene promoter region 
(AF128893) was generated, and the nonsense oligodeoxy-
nucleotide, 5′-GAGCATTAGCACCGCGGGC-3′, was used 
as a negative control in vitro and in vivo. Both of the oli-
godeoxynucleotides were synthesized by SBS Genetech 
(Beijing, China).
PEI  with  a  molecular  weight  of  25  kDm  and 
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (Hepes) 
was purchased from Sigma Corporation (St Louis, MO). 
NGR peptide (CNGRCK2HK3HK11) with or without FAM 
was synthesized by GL Biochem Co Ltd (Shanghai, China), 
with C being cysteine, N being asparagine, G being glycine, 
R being arginine, H being histidine, and K being lysine. 
L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPC)-
trypsin, RPMI-1640 culture medium, and fetal bovine serum 
were obtained from Gibco (Carlsbad, CA). Dextran-70 and 
PEG-6000 were obtained from Amersham Biosciences AB 
(Uppsala, Sweden). Pluronic F-68 was purchased from Fluke 
Corporation (Everett, WA).
Instruments
A zetasizer (Nano ZS90; Malvern, Worcestershire, UK), 
atomic force microscope (SPM-9500J3; Shimadzu, Tokyo, 
Japan), confocal fluorescence microscope (Zeiss, Oberkochen, 
Germany), cell flow cytometer (Partec Company, Munich, 
Germany), and a thin-layer gel optical scanning system (Gene 
Genius, Syngene, Frederick, MD) were used in this study.
cell line and animals
The esophageal carcinoma cell line (EC9706) was gifted by 
the National Laboratory of Molecular Oncology, Chinese 
Academy of Medical Sciences, Beijing, China. The cells 
were maintained in RPMI-1640 medium supplemented with 
10% fetal bovine serum, penicillin 100 IU/mL, and 100 strep-
tomycin IU/mL. The cultures were incubated at 37°C in a 
humidified atmosphere containing 5% CO2. Female BALB/C International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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nude mice (4–6 weeks of age) were purchased from the 
Institute of Laboratory Animal Science, Chinese Academy 
of Medical Sciences, Beijing, China, and housed in the 
pathogen-free animal facility at the Animal Laboratory 
Center of Zhengzhou University. For the esophageal carci-
noma model, EC9706 cells were trypsinized, washed twice 
with phosphate-buffered saline, and injected into the mice 
subcutaneously as 2 × 106 cells into the axillae bilaterally.
PeI/AsON and Ngr/PeI/AsON 
complexes
The PEI/ASON complexes were prepared in 1% Dextran 
solution with 5% glucose at various ratios of PEI nitrogen 
to ASON phosphate (N/P ratio) under different pH condi-
tions. Different amounts of ASON were dissolved, and PEI 
solution was then transferred into these ASON solutions. 
The solutions were vortexed for 20 seconds and left at room 
temperature for 30 minutes. The procedure followed for 
preparation of the NGR/PEI/ASON complexes was the same 
as for the PEI/ASON complexes, except that NGR peptide 
solution was added to the ASON solutions.
size and zeta potential analysis
The PEI/ASON and NGR/PEI/ASON complexes were 
suspended in deionized water at a concentration of 
1 mg/mL to measure their sizes and zeta potentials using 
the Nano ZS90.
Image observation
A 15 µL quantity of each complex solution was dropped onto 
a freshly prepared mica surface to dry at room temperature. 
Images of the PEI/ASON or NGR/PEI/ASON complexes 
were then captured by atomic force microscopy.
Ability of PeI to condense AsON
To determine the ability of PEI to condense ASON, 
increasing amounts of PEI were added to a fixed amount 
(100 µg/mL) of ASON at N/P ratios of 3:0, 3.5, 4.0, 4.5, 
5.0, 6.0, 7.0, 8.0, and 9.0. The complex solutions were 
centrifuged at 12,000 rpm for 10 minutes (HERMLE Z232) 
and then allowed to stand for 1 hour at 4°C. Samples of 
supernatant (5 µL) were loaded onto 1.2% agarose gel in 
Tris-acetate-EDTA buffer and visualized using an ultra-
violet transilluminator.
Protection of AsON against DNase I degradation
The ability of the PEI/ASON complexes to withstand DNase I 
degradation was evaluated. PEI/ASON complexes were 
prepared at an N/P ratio of 4.0 or 10.0 using a final ASON 
concentration of 100 µg/mL. The complexes (17 µL), as well 
as a control solution of ASON, were incubated with DNase I 
1 µL in the presence of 5 mM MgCl2 at 37°C for 1 hour. 
Degradation was stopped by addition of EDTA (final con-
centration 0.05 M). Samples were loaded onto 1.2% agarose 
gel and visualized using an ultraviolet transilluminator.
Uptake of PeI/AsON complexes by ec9706 cells
The in vitro transfection efficacy of PEI/ASON or NGR/PEI/
ASON complexes was evaluated in the EC9706 cell line. 
Cells were seeded in six-well plates at a density of 1 × 106/
well and maintained in RPMI-1640 medium supplemented 
with 10% fetal bovine serum, streptomycin 100 IU/mL, 
penicillin 100 IU/mL, and 4 mM L-glutamine at 37°C in a 
humidified 5% CO2 incubator. During transfection, FAM-
labeled ASON (CASON = 100 µg/mL) complexes (PEI/ASON 
and NGR/PEI/ASON) were added to the EC9706 cells in 
RPMI-1640 medium and incubated for 1.5 hours at 37°C. 
Following incubation, the cells were washed with phosphate-
buffered saline and fixed with cold ethanol for 30 minutes. 
The cells were observed by confocal fluorescence 
microscopy.
In vivo distribution of PeI/AsON or Ngr/PeI/AsON
The mice used in this study were inoculated with 1 × 107 
EC9706 tumor cells in the dorsal flank, and the tumors were 
allowed to grow to a diameter of 0.8–1.0 cm. The mice were 
maintained using a standard diet, bedding, and environment, 
with free access to food and drinking water. Six mice with 
the human esophageal cancer xenografts were randomly 
divided into two groups and injected with NGR/PEI/ASON 
or PEI/ASON complexes through the tail vein.
At hours 1, 3, and 6 after injection, the mice were sacrificed 
by cervical dislocation. The mice were then dissected, and the 
tissues of interest (liver, spleen, lung, kidney, and tumor) were 
collected immediately and frozen in powdered dry ice for 
30 minutes. The prepared specimens were embedded in tissue 
optimum cutting temperature-freeze medium and refrozen for 
cryostat sectioning (3–5 µm in thickness). All tissue samples 
were observed by confocal fluorescence microscopy.
Results and discussion
effects of N/P ratio on size and zeta 
potential of PeI/AsON complexes
As seen in Figure 1, the sizes of the PEI/ASON complexes 
were about 120 nm at N/P ratios of 1.5, 2.0, 4.0, 6.0, 8.0, and 
10.0. However, complexes with N/P ratios of 0.5 and 1.0 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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were flocculated. At N/P ratios of 2.5, 3.0, and 3.5, the sizes 
of PEI/ASON complexes with a low zeta potential (,20 mV) 
became large (about 1 µm), suggesting that these PEI/ASON 
complexes flocculated due to low zeta potentials.
The zeta potential of a gene delivery system is known to 
be one of the major factors influencing its transfection 
efficacy,15 and the zeta potential of PEI/ASON complexes 
appeared to increase with the N/P ratio, ranging from 1.5 
to 10. As indicated in Figure 1, the zeta potential increased 
rapidly according to N/P ratio from 1.5 to 4, but remained 
relatively stable at an N/P ratio of 4 to 10.
The relationship between the N/P ratio and the zeta 
potential of the PEI/ASON complexes was investigated by 
stepwise regression analysis (α = 0.01), and this indicated 
an obvious correlation between the natural logarithm of the 
N/P ratio in the range of 1.5 to 5.0 and the zeta potential, 
with a linear regression equation of Y = −63.486 + 65.988X 
(X and Y represented as the natural logarithm of N/P ratio 
and zeta potential, respectively, r2 = 0.9348).
effects of ph on size and zeta potential  
of PeI/AsON complexes
PEI/ASON complexes with an N/P ratio of 4.0 were prepared 
to test the effect of pH on size and zeta potential. The results 
indicated that the size of the complexes was about 100 nm 
at a pH of 6.5 to 7.5. However, the size increased dramati-
cally to 700 nm at a pH beyond 8.0. No significant change 
in zeta potential was observed at a pH below 7.5, but this 
decreased dramatically at pHs in the range of 7.5 to 9.0 
(Figure 2). These results suggest that pH strongly influences 
the zeta potential of PEI/ASON complexes and that the zeta 
potential is of importance for PEI/ASON complexes to 
remain stable in solution.
effects of polymers on size, zeta potential, 
and stability of complexes
We evaluated the effects of different polymers, including 
Dextran 70, Pluronic F-68, and PEG-6000, on the aggregation 
of PEI/ASON complexes in the presence of RPMI-1640 
culture medium. PEI/ASON complexes at an N/P ratio of 
4.0 was stable in the presence of Dextran 70. Table 1 shows 
the protective effect of Dextran 70 on the PEI/ASON com-
plexes at different concentrations in RPMI-1640 culture 
medium. However, Pluronic F-68 and PEG-6000 did not 
prevent aggregation of the PEI/ASON complexes in RPMI-
1640 culture medium (data not shown).
The effectiveness of Dextran 70 in stabilizing the PEI/
ASON complex could been explained by its dual hydrophobic-
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Figure 1 effects of N/P ratio on size and zeta potential of PeI/AsON complexes. 
Abbreviations: PeI, polyethylenimine; AsON, antisense oligonucleotide.
Table 1 Protective effectiveness of Dextran-70 on PeI/AsON complexes at different concentration
Dextran-70 (%) 0 1 2 3 4 5
size (nm) / 194.2 ± 11.3 264.4 ± 13.2 303.2 ± 18.7 275.1 ± 20.13 363.4 ± 34.9
Note: /, complexes aggregation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 2 effects of ph on size and zeta potential of PeI/AsON complexes. 
Abbreviations: PeI, polyethylenimine; AsON, antisense oligonucleotide.
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Figure 4 Agarose gel electrophoresis of PeI/AsON complexes.
Abbreviations: PeI, polyethylenimine; AsON, antisense oligonucleotide.
hydrophilic nature,16 whereby the long hydrophilic chain of 
the surfactant prevents the complexes from coming into 
contact with each other, while the hydrophobic tail interacts 
with the hydrophobic portion of the PEI/ASON complex.
Ability of PeI to condense AsON
Electrophoresis on agarose gel was used to investigate the 
ability of PEI to condense ASON into PEI/ASON com-
plexes. PEI was able to condense ASON into PEI/ASON 
complexes completely at an N/P ratio $ 6.0 (Figure 3). 
However, a free ASON band occurred at an N/P ratio $ 5.0, 
indicating that PEI could not condense ASON completely 
at higher N/P ratios.
Protection against DNase I degradation
As can be seen in Figures 4 and 5, naked ASON was 
degraded within 1 hour of incubation with DNase I. As 
N/P0 3.0 3.5 4.0 4.5 5.0 6.0 7.0 8.0 9.0
Figure 3 Agarose gel electrophoresis of PeI/AsON complexes at different N/P 
ratios.
Abbreviations: PeI, polyethylenimine; AsON, antisense oligonucleotide.
expected, incorporation of ASON into the complexes 
inhibited the activity of DNase I. Both PEI/ASON and 
NGR/PEI/ASON complexes protected ASON to the same 
extent, regardless of N/P ratio (4.0 or 10.0). This could be 
explained by the fact that DNase I was unable to access 
the entrapped ASON.
The samples of ASON (1), PEI/ASON (N/P 4.0) (3) and 
PEI/ASON (N/P 10.0) (5) complexes were not degraded by 
DNase I. The samples of ASON (2), PEI/ASON (N/P 4.0) 
(4) and PEI/ASON (N/P 10.0) (6) complexes were degraded 
by DNase I (Figure 4).
The samples of ASON (1), NGR/PEI/ASON (N/P 4.0) 
(3) and NGR/PEI/ASON (N/P 10.0) (5) complexes were 
not degraded by DNase I. The samples of ASON (2), 
NGR/PEI/ASON (N/P 4.0) (4) and NGR/PEI/ASON (N/P 
10.0) (6) complexes were not degraded by DNase I 
(Figure 5).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Image of PeI/AsON  
and Ngr/PeI/AsON complexes
The images showed that the PEI/ASON and NGR/PEI/ASON 
complexes were of a uniform, smooth-surfaced, and spherical 
shape (Figure 6).
cellular uptake of PeI/AsON  
and Ngr/PeI/AsON
FAM-labeled ASON was used to evaluate cellular uptake of 
the PEI/ASON and NGR/PEI/ASON complexes. Human 
esophageal cancer EC9706 cells were treated with naked 
ASON, PEI/ASON, and NGR/PEI/ASON complexes, and 
their cellular uptake was observed by confocal fluorescence 
microscopy. The intracellular fluorescence intensity in 
EC9706 cells treated with PEI/ASON or NGR/PEI/ASON 
complexes was stronger than that in EC9706 cells treated 
with naked ASON at 24 hours after treatment, indicating that 
the ASON/PEI and NGR/PEI/ASON complexes enhanced 
uptake of ASON by the EC9706 cells. However, no obvious 
differences between the groups of ASON/PEI and NGR/PEI/
ASON complexes were found (Figure 7).
PeI/AsON and Ngr/PeI/AsON 
biodistribution in tumor-bearing mice
Liver, kidney, lung, heart, brain, and tumor tissues were 
removed from the mice to prepare frozen sections at hours 
1, 3, and 6 after injection of the NGR/PEI/ASON or PEI/
ASON complexes. All samples were then observed by confo-
cal fluorescence microscopy. Fluorescence intensity was 
strongest in the kidney and liver, followed by the lung and 
tumor tissue, and increased in these organs from 1–6 hours 
(Figure 8), indicating that the NGR/PEI/ASON complexes 
had a half-life of at least 6 hours. None of the other organs 
1234 56
Figure 5 Agarose gel electrophoresis of Ngr/PeI/AsON complexes.
Abbreviations:  PeI,  polyethylenimine;  AsON,  antisense  oligonucleotide;  Ngr, 
asparagine-glycine-arginine peptide.
Figure 6 Upper PeI/AsON complexes; Lower Ngr/PeI/AsON complexes.
Abbreviations: PeI, polyethylenimine; AsON, antisense oligonucleotide; Ngr, asparagine-glycine-arginine peptide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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or tissues of mice injected with FAM-labeled ASON showed 
strong fluorescent intensity. High fluorescence accumulation 
in the kidney indicated that ASON was cleared primarily by 
the renal route.
Biodistribution of the PEI/ASON complexes was similar 
to that of the NGR/PEI/ASON complexes, except for their 
uptake in tumor cells. Tumor uptake increased gradually 
from 1–6 hours after injection of the NGR/PEI/ASON com-
plexes, but this trend was not evident after injection of the 
PEI/ASON complexes. In comparison with the fluorescent 
tumor intensity in the mice injected with the NGR/PEI/ASON 
complexes, the fluorescent intensity in the tumors of mice 
injected with PEI/ASON was significantly lower, suggesting 
that the NGR peptide may enhance the ability of an ASON 
delivery system to home to tumor tissues. NGR peptide or 
its analog could be a useful component in delivery systems 
for cancer drugs.
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